Variant Bio Launches AI Platform for Drug Discovery in $120 Million Deal with Boehringer Ingelheim
Variant Bio has introduced its Inference platform, using AI for drug discovery, and secured a collaboration with Boehringer Ingelheim, potentially worth over $120 million. The announcement signals a shift towards AI in pharmaceuticals, driven by FDA regulations to minimize animal testing.
Insights:
Variant Bio has unveiled its latest innovation, the Inference platform, an AI-powered system designed to revolutionize drug discovery by leveraging genomic and biological data. The launch was announced on Tuesday, January 6, marking a significant milestone for the company. The platform utilizes agentic AI to analyze both proprietary and public human genomic data alongside large-scale biological datasets to accelerate the drug discovery process.
In conjunction with the platform's launch, Variant Bio disclosed a multi-year research collaboration and licensing agreement with pharmaceutical giant Boehringer Ingelheim. This partnership, focused on discovering new treatments for kidney disease, promises Variant Bio an upfront payment and potential license and milestone payments totaling over $120 million. This collaboration underscores the commercial viability of AI-driven drug discovery, with Variant Bio's total collaborations exceeding $200 million.
